Gregory T. Went, PhD | Chairman and Chief Executive Officer
Dr. Went is the founder, chairman, and CEO of Adamas Pharmaceuticals and has guided the company’s growth from inception in 2000. Dr. Went developed the original scientific approach, based upon the understanding and modeling of time-dependent biological phenomena. He has steered Adamas through the licensing of assets related to Namenda XR and Namzaric to Forest Laboratories (now Allergan), the company’s IPO, and steered the company through the development of Gocovri and the commercial launch of a new medicine for patients with Parkinson’s disease. Prior to Adamas, Dr. Went co-founded CuraGen Corporation in 1992, one of the first genomics companies, where he served as executive vice president and director. Dr. Went has served on the board of directors of Angelica, Parallele Biosciences, and Tethys Biosciences.
Dr. Went has published in the fields of catalysis, spectroscopy, DNA sequencing, gene expression profiling, neuroscience, influenza, and neurology. Dr. Went is an inventor on more than 70 issued and pending patents. He received his PhD in chemical engineering from the University of California, Berkeley, his BS in chemical engineering from Carnegie Mellon University, and did additional post-doctoral work at Cornell University.
Michael F. Bigham
Mr. Bigham currently serves as chief executive officer and chairman of the board of directors of Paratek Pharmaceuticals, Inc. He has more than 25 years of senior leadership experience in the biopharmaceutical industry. From 2003 to 2015, Mr. Bigham was a partner at Abingworth LLP, an international investment group dedicated to life sciences and healthcare. Earlier in his career, he served as chairman and chief executive officer of Coulter Pharmaceuticals up until the company’s acquisition by Corixa. Mr. Bigham currently is a member of the board of directors of InMediata and has held several directorships, including Avila Therapeutics, Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals, Avedro, and Valeritas. He received his BS from the University of Virginia and his MBA from Stanford University.
Mardi C. Dier
Ms. Dier serves as Executive Vice President and Chief Financial Officer of Portola Pharmaceuticals since November 2013 after joining the company in August 2006. Previously, she served as Vice President of Investor Relations at Chiron Corporation from 2003 until its acquisition by Novartis Pharmaceuticals in April 2006. Prior to joining Chiron, she served as a Director in the West Coast investment banking practice at Prudential Securities, where she focused on biotechnology and other life sciences companies. Ms. Dier was previously at KPMG Peat Marwick in the audit department. She holds a B.S. in biology from Stanford University and an M.B.A. from The Anderson School at the University of California, Los Angeles. In 2013, Ms. Dier was recognized as one of the most influential Bay Area business women by the San Francisco Business Times and was a finalist for its Bay Area CFO of the Year Award.
Martha J. Demski
Ms. Demski has more than 30 years of experience in the fields of finance and biotechnology. She is on the board of directors of Chimerix, Inc., where she chairs the audit committee and serves on the nominating and governance committee. She also chairs the audit committee and serves on the compensation committee at Neothetics, Inc. Previously, Ms. Demski served as senior vice president and chief financial officer of Ajinomoto Althea, Inc., as well as interim chief operating officer and chief financial officer of the Sidney Kimmel Cancer Center. She has also served as chief financial officer of Vical Incorporated, where she was responsible for multiple private and public financings, including the company’s initial public offering. Additionally, Ms. Demski also has more than 13 years of banking experience with Bank of America and US Trust. She holds an MBA from The University of Chicago Booth School of Business and a BA from Michigan State University.
William Ericson, JD
Mr. Ericson is a managing partner of Mohr Davidow Ventures and a managing director of Wildcat Venture Partners. He currently serves on the board of directors of Pacific Biosciences and Rocket Fuel, as well as the boards of a number of privately held software and healthcare companies. Mr. Ericson received his BSFS from Georgetown University of Foreign Service and his JD from Northwestern University School of Law.
Ivan Lieberburg, MD, PhD
Dr. Lieberburg is currently a member of the Tavistock Group, a private equity firm, where he concentrates on healthcare and life sciences investment opportunities. Prior to joining Tavistock in 2009, Dr. Lieberburg was employed at Elan Corporation, plc for 22 years, where he most recently served as executive vice president in the Corporate Office of Technology, and chief medical officer. Prior to joining Elan (formerly Athena Neurosciences, Inc.) in 1987, Dr. Lieberburg held faculty positions at Albert Einstein School of Medicine and Mount Sinai School of Medicine. He holds a PhD from Rockefeller University and an MD from the University of Miami. Dr. Lieberburg is the author of more than 100 publications and an inventor on 29 patents and patent applications.
John MacPhee, MPH
Mr. MacPhee serves as chief executive officer of The JED Foundation, a nonprofit organization that exists to reduce the risks of substance abuse, self-harm, and suicide and to help young adults thrive. Prior to JED, he served as executive vice president of Par Pharmaceutical and president of Par’s Strativa Pharmaceuticals division, where he oversaw commercial operations, clinical development, medical affairs, and business development. Previously, he worked at Forest Laboratories, where he led the launches of Celexa® (citalopram), Lexapro® (escitalopram), and Namenda® (memantine HCl). Mr. MacPhee also serves as a board member for Bottom Line, a nonprofit organization that provides guidance counseling to disadvantaged urban youth to help them get into college and graduate. He earned a BA from Columbia College, an MBA from New York University, and an MPH from Columbia University.
David L. Mahoney
Mr. Mahoney is a private equity investor and currently serves on the board of directors of Symantec Corporation, Corcept Therapeutics, and Mercy Corps, and as a Trustee of the Schwab Mutual Funds and SFMOMA. Previously, Mr. Mahoney acted as co-chief executive officer of McKesson HBOC, Inc. (now McKesson Corporation) and as chief executive officer of McKesson LLC from July 1999 to February 2001. He joined McKesson in 1990 as Vice President for Strategic Planning and managed the company's relationships with the pharmaceutical industry. Prior to joining McKesson, Mr. Mahoney was a principal with McKinsey & Company from 1981 to 1990. Mr. Mahoney is an honors graduate from Harvard Business School and Princeton University.